Royal Bank Of Canada Aytu Biopharma, Inc Transaction History

Royal Bank Of Canada

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.15 - $4.0 $4 - $128	32 Added 6.68%	511 $0
Q3 2022 Nov 14, 2022	BUY	$0.19 - $3.8 $0 - $11	3 Added 0.63%	479 $0
Q1 2022 May 16, 2022	SELL	$1.08 - $1.55 $34 - $49	-32 Reduced 6.3%	476 $1,000
Q4 2021 Feb 14, 2022	SELL	$1.35 - $2.95 $102 - $224	-76 Reduced 13.01%	508 $1,000
Q3 2021 Nov 15, 2021	SELL	$2.78 - $5.12 $14,400 - $26,521	-5,180 Reduced 89.87%	584 $1,000
Q2 2021 Aug 16, 2021	BUY	$4.73 - $7.56 $27,263 - $43,575	5,764 New	5,764 $29,000

Ticker AYTU
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 62,432,700
Market Cap $88.7M
Description
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT f...

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

Stay updated on Royal Bank Of Canada with notifications on news.